JP2014201568A5 - - Google Patents

Download PDF

Info

Publication number
JP2014201568A5
JP2014201568A5 JP2013080907A JP2013080907A JP2014201568A5 JP 2014201568 A5 JP2014201568 A5 JP 2014201568A5 JP 2013080907 A JP2013080907 A JP 2013080907A JP 2013080907 A JP2013080907 A JP 2013080907A JP 2014201568 A5 JP2014201568 A5 JP 2014201568A5
Authority
JP
Japan
Prior art keywords
extract
active ingredient
prickly pear
food composition
ameliorating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013080907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014201568A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013080907A priority Critical patent/JP2014201568A/ja
Priority claimed from JP2013080907A external-priority patent/JP2014201568A/ja
Publication of JP2014201568A publication Critical patent/JP2014201568A/ja
Publication of JP2014201568A5 publication Critical patent/JP2014201568A5/ja
Pending legal-status Critical Current

Links

JP2013080907A 2013-04-09 2013-04-09 Glp−1分泌促進剤 Pending JP2014201568A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013080907A JP2014201568A (ja) 2013-04-09 2013-04-09 Glp−1分泌促進剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013080907A JP2014201568A (ja) 2013-04-09 2013-04-09 Glp−1分泌促進剤

Publications (2)

Publication Number Publication Date
JP2014201568A JP2014201568A (ja) 2014-10-27
JP2014201568A5 true JP2014201568A5 (https=) 2016-07-07

Family

ID=52352331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013080907A Pending JP2014201568A (ja) 2013-04-09 2013-04-09 Glp−1分泌促進剤

Country Status (1)

Country Link
JP (1) JP2014201568A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220395476A1 (en) * 2019-09-30 2022-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Drug for treating artery-related diseases, and use thereof

Similar Documents

Publication Publication Date Title
MY188344A (en) Extract formulations of rhodamnia cinerea and uses thereof
MX391293B (es) DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS.
HK1211232A1 (en) Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
HK1207097A1 (en) Fusion proteins for treating a metabolic syndrome
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
PH12018500261B1 (en) Azole benzene derivative
WO2010087565A3 (ko) 피페린의 신규한 용도
TN2018000038A1 (en) Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
PH12017501205A1 (en) Glucagon derivatives
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
JP2014201568A5 (https=)
WO2015042495A3 (en) Metformin salts to treat type2 diabetes
JP2014201567A5 (https=)
MX346646B (es) Formulacion farmaceutica de decavanadato de 4-dimetilaminopiridini o y sus derivados, para la prevencion y tratamiento del sindrome metabolico, obesidad y diabetes tipo 2.
CR20190161A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terpéutico del mismo
MX2015009557A (es) Uso insulinomimetico de compuestos no-peptidicos con vanadio y sus derivados.